Neurocentre Magendie - U1215: Dépôts récents
Voici les éléments 1-20 de 360
-
Individual variations in motives for nicotine self-administration in male rats: evidence in support for a precision psychopharmacology.
(Translational psychiatry. vol. 14, n° 1, pp. 85, 2024-02-09)Article de revueLibre accès -
Neurosarcoidosis: Clinical, biological, and MRI presentation of central nervous system disease in a national multicenter cohort
(Brain and Behavior. vol. 14, n° 9, pp. 3443, 2024-09)Article de revueLibre accès -
Genetic labeling of embryonically-born dentate granule neurons in young mice using the PenkCre mouse line
(Scientific Reports. vol. 14, n° 1, pp. 5022, 2024-02-29)Article de revueLibre accès -
A plastic aggrecan barrier modulated by peripheral energy state gates metabolic signal access to arcuate neurons
(Nature Communications. vol. 15, n° 1, pp. 6701, 2024-08-07)Article de revueLibre accès -
Early Maintenance Treatment Initiation and Relapse Risk Mitigation After a First Event of MOGAD in Adults
(Neurology. vol. 103, n° 3, pp. e209624, 2024-08-13)Article de revue -
“Cooperation between physicians and physios fosters trust you know”: a qualitative study exploring patients' experience with first-contact physiotherapy for low back pain in French primary care
(BMC Primary Care. vol. 25, n° 1, pp. 69, 2024-02-23)Article de revueLibre accès -
The diagnostic workup of children with the radiologically isolated syndrome differs by age and by sex
(Journal of Neurology. vol. 271, n° 7, pp. 4019-4027, 2024-07)Article de revueLibre accès -
Acute Clinical Events Identified as Relapses With Stable Magnetic Resonance Imaging in Multiple Sclerosis
(JAMA neurology. vol. 81, n° 8, pp. 814-823, 2024-08)Article de revue -
Advocating for rituximab as first-line treatment for NMOSD-AQP4 patients in France: Cost and efficacy considerations
(Revue Neurologique. vol. 180, n° 8, pp. 711-714, 2024-10)Article de revue -
Prenatal maternal negative life events associated with child emotional and behavioral problems in the French EDEN cohort
(Journal of Affective Disorders. vol. 356, pp. 224-232, 2024-07-01)Article de revueLibre accès -
Manipulating Stem Cell Fate with Disordered Bioactive Cues on Surfaces: The Role of Bioactive Ligand Selection
(ACS Applied Materials & Interfaces. vol. 16, n° 15, pp. 18474-18489, 2024-04-17)Article de revueLibre accès -
Therapeutic efficacy of the BKCa channel opener chlorzoxazone in a mouse model of Fragile X syndrome
(Neuropsychopharmacology. vol. 49, n° 13, pp. 2032-2041, 2024-12)Article de revueLibre accès -
Dye-Based Fluorescent Organic Nanoparticles, New Promising Tools for Optogenetics
(Advanced Healthcare Materials. vol. 14, n° 2, pp. e2402132, 2025-01)Article de revueDemander une copie -
Vulnerability of Thalamic Nuclei at CSF Interface During the Entire Course of Multiple Sclerosis
(Neurology Neuroimmunology & Neuroinflammation. vol. 11, n° 3, 2024-05)Article de revueLibre accès -
Impact of exenatide on weight loss and eating behavior in adults with craniopharyngioma-related obesity: the CRANIOEXE randomized placebo-controlled trial
(European Journal of Endocrinology. vol. 190, n° 4, pp. 257-265, 2024-04-30)Article de revue -
Impact of psychedelics on craving in addiction: A systematic review
(Journal of Psychopharmacology. pp. 2698811241308613, 2025-02-01)Article de revue -
Stress and Microglia: A Double-edged Relationship
(Advances in neurobiology. vol. 37, pp. 333 – 342, 2024-08-30)Article de revue -
Hypothalamic Glucose Hypersensitivity-Induced Insulin Secretion in the Obese Zücker Rat Is Reversed by Central Ghrelin Treatment
(Antioxidants and Redox Signaling. vol. 40, n° 13-15, pp. 837 – 849, 2024)Article de revueLibre accès -
Shorter infusion time of ocrelizumab: Results from the randomized, double-blind ENSEMBLE PLUS substudy in patients with relapsing-remitting multiple sclerosis
(Multiple Sclerosis and Related Disorders. vol. 46, n° 102492, 2020-11)Article de revueLibre accès